XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

Novo Nordisk's Wegovy weight-loss drug approved in China



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 5-Novo Nordisk's Wegovy weight-loss drug approved in China</title></head><body>

Added comment from Raffles Hospital Beijing marketing manager and Novo Nordisk

By Andrew Silver

SHANGHAI, June 25 (Reuters) -Novo Nordisk's NOVOb.CO hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and the country estimated to hold the highest number of overweight or obese people.

The company will communicate details on pricing and availability when it launches, it told Reuters in a statement. Novo said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug.

Raffles Hospital Beijing, a major hospital in the Chinese capital, might place an order around September, but concrete timing is uncertain, Rose Niu Wei, a marketing manager at the private hospital, told Reuters.

By 1000 GMT on Tuesday Novo's shares were up 1.5%, having earlier touched record highs that valued the company at nearly $490 billion.

The number of overweight adults in China, the world's second most populous country, is projected to reach 540 million by 2030, 2.8 times higher than 2000 levels, a Chinese public health study showed in 2020. Numbers who are obese are seen jumping 7.5 times to 150 million.

But Novo may have a much shorter time in the Chinese market to make the most of its early-mover advantage in weight-loss drugs.

Its patent on semaglutide, the key ingredient in Wegovy and its diabetes drug Ozempic, is set to expire in less than two years in China compared to in 2031 in Europe and Japan and in 2032 in the U.S, and local drugmakers are racing to develop generic or biosimilar versions.

Novo is also in the midst of a legal fight in China over the patent, an adverse ruling in which could make it lose its semaglutide exclusivity even sooner. That would make China the first major market where it is stripped of patent protection for the drugs.

Booming demand for Wegovy has propelled Novo's shares to record highs, and the company last year overtook LVMH LVMH.PA to become Europe's most valuable listed company.

But its success has left Novo facing shortages and forced to limit the number of patients taking the once-weekly injection.

"At the moment capacity and not global demand is the main limit on how fast (sales volumes) can grow, and adding a huge Chinese market will only increase the need for more capacity," said Allan von Mehren, China economist at Danske Bank.

"It is hard to say how fast volumes can go up, but the potential should be big."

The group faces competition from rival Eli Lilly LLY.N, whose diabetes drug tirzepatide received approval from China in May. Some analysts expect Zepound, the U.S. firm's weight-loss drug with the same active ingredient, will be approved in China this year or in the first half of 2025.

Both Eli Lilly and Novo are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by the decade's end. Both companies' obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.

Novo announced on Monday a $4.1 billion investment to build a U.S. facility to fill injection pens for Wegovy and Ozempic.

Ozempic won approval from China in 2021, and Novo saw sales of the drug in the greater China region double to 4.8 billion Danish crowns ($698 million) last year.

At least two Chinese firms, Livzon Pharmaceutical Group 000513.SZ and Hangzhou Jiuyuan Gene Engineering, have already applied to begin commercial sales of Ozempic copies.

Shares in Livzon finished unchanged, while major Jiuyuan Gene shareholder Huadong Medicine 000963.SZ closed down 0.3%.



Wegovy sales propel Novo Nordisk shares https://tmsnrt.rs/4eCpkXm


Reporting by Andrew Silver; Editing by Tomasz Janowski, Miyoung Kim, Edwina Gibbs and Jan Harvey

</body></html>

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.